NCT06157892 2026-03-17
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06003231 2026-03-16
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
NCT07446452 2026-03-03
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT07285941 2025-12-16
Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT07065435 2025-07-15
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT06063018 2023-10-02
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT05979740 2023-08-31
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
RenJi Hospital
Phase 2 Unknown
NCT05898373 2023-06-12
Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
Peking Union Medical College
Phase 1/2 Not yet recruiting
NCT05241899 2022-02-16
A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown